TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11013186

Group type: EXPERIMENTAL
Intervention: LASIK for secondary hyperopia
Number of subjects: 30
Study: 8635380

Group type: EXPERIMENTAL
Intervention: 30 mg Morphine plus 25 mg Promethazine (M-P)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 mg Morphine (M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 mg Morphine plus 10 mg Prochlorperazine (M-PC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study: 1461870

Group type: EXPERIMENTAL
Intervention: Dobutamine (high doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine (high doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dobutamine (low doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine (low doses)
Number of subjects: 0
Study: 3867301

Group type: EXPERIMENTAL
Intervention: Cranial irradiation (24Gy) plus i.t. MTX, 6 doses (Modality A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: i.t. MTX and ARA-C, 10 doses (6 weekly and 4 monthly) (Modality B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard-risk (SR) therapy with PRED, VCR, ASPAR for remission induction and MP and MTX for maintenance
Number of subjects: 76

Group type: COMPARATOR
Intervention: High-risk (HR) therapy with 4 drugs including DAUNO, PRED, VCR, and DAUNO for reinductions every 3 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Continuous use of cotrimoxazole
Number of subjects: 76
Study: 29305245

Group type: EXPERIMENTAL
Intervention: supplemental home parenteral nutrition (sHPN)
Number of subjects: 47

Group type: COMPARATOR
Intervention: best practice nutritional care and dietetic counselling (non-sHPN)
Number of subjects: 47
Study: 29043918

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 58
Study: 26325232

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose ICS
Number of subjects: 40
Study: 25419743

Group type: EXPERIMENTAL
Intervention: Livestock/animal asset value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conflict-related traumatic events
Number of subjects: 0
Study: 22859563

Group type: EXPERIMENTAL
Intervention: Concomitant boost (CCB) with a median dose of 66 Gy and median overall treatment time (OTT) of 40 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with a median dose of 60 Gy and median OTT of 47 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall treatment time (OTT) ≤42 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall treatment time (OTT) ≥43 days
Number of subjects: 16
Study: 19841476

Group type: EXPERIMENTAL
Intervention: Nelotanserin (up to 40 mg)
Number of subjects: 0
Study: 17914653

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.54 percent continuous wound infusion
Number of subjects: 310

Group type: COMPARATOR
Intervention: Normal saline continuous wound infusion
Number of subjects: 310
Study: 15983144

Group type: EXPERIMENTAL
Intervention: LCT/MCT propofol
Number of subjects: 200

Group type: COMPARATOR
Intervention: LCT propofol
Number of subjects: 200
Study: 12850358

Group type: EXPERIMENTAL
Intervention: Pnc PS vaccine (N=106)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (TT only, N=54)
Number of subjects: 160
Study: 10097952

Group type: EXPERIMENTAL
Intervention: 9 million IU IFN alpha subcutaneously 5 times weekly and 6 million IU IL-2 subcutaneously twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 million IU IFN alpha and 6 million IU IL-2
Number of subjects: 0
Study: 8904969

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication in women (both normally cycling and those taking oral contraceptives)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High estrogen phases in women
Number of subjects: 2

Group type: COMPARATOR
Intervention: Men
Number of subjects: 2
Study: 1651210

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 223
Study: 7093092

Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg orally twice daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Labetalol 0.6 mg/kg intravenous dose
Number of subjects: 19
Study: 30205445

Group type: EXPERIMENTAL
Intervention: High-Intensity Nordic Walking (HI-NW) with Vitamin D supplementation (4000 IU/day or 800 IU/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Nordic Walking (MI-NW) with High Dose Vitamin D supplementation (4000 IU/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate-Intensity Nordic Walking (MI-NW) with Low Dose Vitamin D supplementation (800 IU/day)
Number of subjects: 42
Study: 26507685

Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 30 mg once daily for up to 24 weeks
Number of subjects: 10
Study: 25527262

Group type: EXPERIMENTAL
Intervention: Stretching Routine (SR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warm-up Routine (WR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 18
Study: 23377516

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (CPS)
Number of subjects: 0
Study: 19997953

Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy (LH)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional open hemorrhoidectomy (OH)
Number of subjects: 84
Study: 18677673

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification and pharmacological treatment
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1510
Study: 15960709

Group type: EXPERIMENTAL
Intervention: Oral penicillin - 800,000 U penicillin G potassium twice daily for 12 days, repeated every 3 months for 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine - 6 mg/kg bodyweight for 12 days, repeated every 3 months for 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical antiseptic (betadine ointment)
Number of subjects: 100
Study: 12505919

Group type: EXPERIMENTAL
Intervention: Continuous IV weight‐adjusted infusion of remifentanil (RIVA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Target-controlled infusion for remifentanil (TCIR)
Number of subjects: 46
Study: 11049237

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (pethidine-inhalational entonox)
Number of subjects: 123
Study: 9172806

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant (PBSCT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Autologous Bone Marrow Transplant (ABMT)
Number of subjects: 76
Study: 1825332

Group type: EXPERIMENTAL
Intervention: PT-01 applied (T)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo applied (P)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control sites (C)
Number of subjects: 27
Study: 6206093

Group type: EXPERIMENTAL
Intervention: Prescreening Developmental Questionnaire (PDQ)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Modified PDQ (PDQ-M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alpern-Boll Developmental Profile II
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PDQ and PDQ-M
Number of subjects: 90
Study: 30702789

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate
Number of subjects: 26
Study: 30853260

Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided injections into the joint capsule (group 1)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Blind injections to the point of maximum tenderness using sham radiographs (group 2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided injections (group 1)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Blind injections (group 2)
Number of subjects: 125
Study: 28791986

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - sexual abuse
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - psychological abuse
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - danger assessment (femicide risk)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - overall
Number of subjects: 207
Study: 26767263

Group type: EXPERIMENTAL
Intervention: General population (adults and children)
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides infection
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Trichuris trichura infection
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Enterobius vermicularis infection in children
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Clonorchis sinensis infection
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Knowledge of prevention and control of parasites
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Healthy behaviors (washing hands before meal)
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Healthy behaviors (washing hands after toilet)
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Healthy behaviors (washing fruits and vegetables before eating)
Number of subjects: 9538

Group type: EXPERIMENTAL
Intervention: Healthy behaviors (never drinking unboiled water)
Number of subjects: 9538
Study: 23386552

Group type: EXPERIMENTAL
Intervention: Intervention hostel group (30 dyads)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison hostels group (29 dyads)
Number of subjects: 59
Study: 20851820

Group type: EXPERIMENTAL
Intervention: Venesection
Number of subjects: 198

Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 198
Study: 17609220

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid (20 mg of prednisolone)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 14
Study: 16469157

Group type: EXPERIMENTAL
Intervention: Animal-source foods supplementation
Number of subjects: 544
Study: 12617741

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre after endotracheal suctioning
Number of subjects: 8

Group type: COMPARATOR
Intervention: Endotracheal suctioning without lung recruitment manoeuvre
Number of subjects: 8
Study: 10684185

Group type: EXPERIMENTAL
Intervention: Early video-endoscopic procedures (9 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative management (43 patients)
Number of subjects: 52
Study: 9059095

Group type: EXPERIMENTAL
Intervention: 6.0-mm reinforced tracheal tube (group F6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngeal mask (group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8.0-mm reinforced tracheal tube (group F8)
Number of subjects: 60
Study: 8373609

Group type: EXPERIMENTAL
Intervention: Bubble inclinometer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thiopental sodium (4 mg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 50
Study: 2425671

Group type: COMPARATOR
Intervention: Urokinase (UK) - 2.83 X 10(5) units by six-hour intravenous drip infusion
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combined Urokinase (UK) and Dextran Sulfate (DS) - UK: 2.84 X 10(5) units and DS: 3000 mg for one day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Urokinase (UK) alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combined Urokinase (UK) and Dextran Sulfate (DS)
Number of subjects: 143
Study: 30589043

Group type: EXPERIMENTAL
Intervention: Parecoxib + TAP block + postoperative PCIA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TAP block + postoperative PCIA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Parecoxib + postoperative PCIA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal saline + postoperative PCIA)
Number of subjects: 80
Study: 27664021

Group type: EXPERIMENTAL
Intervention: Phentermine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 24906915

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 40
Study: 22668958

Group type: EXPERIMENTAL
Intervention: Phaco-emulsification cataract surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual small-incision cataract surgery
Number of subjects: 200
Study: 21152831

Group type: EXPERIMENTAL
Intervention: Soy protein plus exercise (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo plus exercise (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo and no exercise (G4)
Number of subjects: 60
Study: 18849624

Group type: EXPERIMENTAL
Intervention: Würzburg bleb classification score (WBCS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mean of all 3 raters using WBCS
Number of subjects: 104
Study: 16433601

Group type: EXPERIMENTAL
Intervention: Aggressive treatment (acetaminophen 650 mg every 6 h for temperature >38.5 degrees C and cooling blanket for temperature >39.5 degrees C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Permissive treatment (no treatment for temperature >38.5 degrees C, treatment initiated at temperature >40 degrees C with acetaminophen and cooling blankets)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Aggressive treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Permissive treatment
Number of subjects: 82
Study: 14597105

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-beta-1a (Rebif(R)) therapy for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior to treatment
Number of subjects: 0
Study: 10595630

Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg/od
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/od
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg/od
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ticlopidine 250 mg/bid
Number of subjects: 62
Study: 8911882

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amisulpride 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg and 200 mg
Number of subjects: 18
Study: 1988333

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sclerotherapy (in alcoholic patients)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonalcoholic patients
Number of subjects: 99

Group type: COMPARATOR
Intervention: Large varices
Number of subjects: 99

Group type: COMPARATOR
Intervention: Wedged hepatic vein pressure < 12 mm Hg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Elective sclerotherapy
Number of subjects: 99
Study: 6108756

Group type: EXPERIMENTAL
Intervention: Oral beta-blockers (atenolol and propranolol) combined with topical epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol (local beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol combined with epinephrine eyedrops
Number of subjects: 0
Study: 30778688

Group type: COMPARATOR
Intervention: Diode laser (940 nm for 1 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (2780 nm, pulse width 140-200 μs)
Number of subjects: 17
Study: 25348661

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN) add-on therapy (180 µg/week)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Entecavir (ETV) monotherapy (0.5 mg/day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN) add-on therapy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 175
Study: 23600919

Group type: EXPERIMENTAL
Intervention: 25-gauge needle (25G)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 22-gauge needle (22G)
Number of subjects: 188
Study: 17413102

Group type: EXPERIMENTAL
Intervention: Fluid skim milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soy-protein beverage
Number of subjects: 0
Study: 15323413

Group type: EXPERIMENTAL
Intervention: Academic consultation
Number of subjects: 36
Study: 11240877

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spontaneous breathing (S)
Number of subjects: 60
Study: 9447901

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for seven days, 500 mg b.i.d. (Group 1, 25 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for ten days, 750 mg b.i.d. (Group 2, 25 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 8514551

Group type: EXPERIMENTAL
Intervention: 75.6 CGE (50.4 Gy by 107-25 MV photons + 25.2 CGE by protons)
Number of subjects: 191

Group type: COMPARATOR
Intervention: 67.2 CGE (10-25 MV photons)
Number of subjects: 191
Study: 2881038

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (20 mg/kg intramuscularly daily for the first 3 days of life)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control (no vitamin E supplementation)
Number of subjects: 231
Study: 30784636

Group type: EXPERIMENTAL
Intervention: Alive & Thrive initiative
Number of subjects: 2288

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2288
Study: 29791011

Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate (MTX)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 187
Study: 27068332

Group type: EXPERIMENTAL
Intervention: Barnidipine + losartan
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lercanidipine + losartan
Number of subjects: 151
Study: 25196897

Group type: EXPERIMENTAL
Intervention: Recombinant FVIII Fc fusion protein (rFVIIIFc) individualized prophylaxis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant FVIII Fc fusion protein (rFVIIIFc) weekly prophylaxis
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard FVIII regimen (pre-study)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Simulated dosing regimens for rFVIIIFc
Number of subjects: 96
Study: 21666531

Group type: EXPERIMENTAL
Intervention: Infant Flow nasal continuous positive airway pressure
Number of subjects: 276

Group type: COMPARATOR
Intervention: Constant flow nasal continuous positive airway pressure
Number of subjects: 276
Study: 20716819

Group type: EXPERIMENTAL
Intervention: REAC-CRM therapy
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo REAC-CRM therapy
Number of subjects: 888
Study: 17935749

Group type: EXPERIMENTAL
Intervention: Long-term adaptation (5s) to a female face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term adaptation (500 ms) to a female face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term adaptation (5s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term adaptation (500 ms)
Number of subjects: 0
Study: 16298065

Group type: EXPERIMENTAL
Intervention: Ascending series of contact heat stimuli rated for pain intensity (VAS-I)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ascending series of contact heat stimuli rated for unpleasantness (VAS-A)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Random series of contact heat stimuli rated for pain intensity (VAS-I)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Random series of contact heat stimuli rated for unpleasantness (VAS-A)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall variance in pain ratings
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Model fit for curve fitting
Number of subjects: 175
Study: 12046340

Group type: EXPERIMENTAL
Intervention: Symmetrical left ventricular hypertrophy (group I)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Asymmetrical left ventricular hypertrophy (group II)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects, group III)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 47
Study: 10439882

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 7812559

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2128472

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Procaine penicillin (PP)
Number of subjects: 311
Study: 498954

Group type: EXPERIMENTAL
Intervention: Transluminal recanalization of occluded coronary artery
Number of subjects: 10
Study: 31113841

Group type: EXPERIMENTAL
Intervention: Onalespib (220 mg/m2 once weekly for 3 of 4 weeks) + Abiraterone Acetate + Prednisone/Prednisolone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Onalespib (120 mg/m2 on day 1 and day 2 weekly for 3 of 4 weeks) + Abiraterone Acetate + Prednisone/Prednisolone
Number of subjects: 48
Study: 28600160

Group type: EXPERIMENTAL
Intervention: Family-based, multi-component intervention including anticipatory guidance on breastfeeding, responsive feeding, non-food soothing techniques, complementary feeding, infant sleep, and minimizing TV/media, delivered through 6 home visits, 4 newsletters, and twice-weekly text messaging.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Family-based, multi-component intervention
Number of subjects: 468

Group type: COMPARATOR
Intervention: Child safety attention-control group
Number of subjects: 468
Study: 25619685

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24013703

Group type: EXPERIMENTAL
Intervention: DC fibber
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Burst fibber
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Shock-on-T
Number of subjects: 14
Study: 22619904

Group type: EXPERIMENTAL
Intervention: Polyethylene bag
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard thermal care (control)
Number of subjects: 38
Study: 19349551

Group type: EXPERIMENTAL
Intervention: Presurgical stress management intervention (SM)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Supportive attention group (SA)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard care group (SC)
Number of subjects: 159
Study: 17210431

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with subacromial decompression
Number of subjects: 80

Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without subacromial decompression
Number of subjects: 80